HomeCompareGARPY vs ABBV

GARPY vs ABBV: Dividend Comparison 2026

GARPY yields 2.61% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GARPY wins by $99.4K in total portfolio value· pulled ahead in Year 7
10 years
GARPY
GARPY
● Live price
2.61%
Share price
$23.70
Annual div
$0.62
5Y div CAGR
52.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$204.1K
Annual income
$95,539.01
Full GARPY calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — GARPY vs ABBV

📍 GARPY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGARPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GARPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GARPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GARPY
Annual income on $10K today (after 15% tax)
$222.01/yr
After 10yr DRIP, annual income (after tax)
$81,208.16/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, GARPY beats the other by $59,341.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GARPY + ABBV for your $10,000?

GARPY: 50%ABBV: 50%
100% ABBV50/50100% GARPY
Portfolio after 10yr
$154.4K
Annual income
$60,632.37/yr
Blended yield
39.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GARPY
No analyst data
Altman Z
2.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GARPY buys
0
ABBV buys
0
No recent congressional trades found for GARPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGARPYABBV
Forward yield2.61%3.12%
Annual dividend / share$0.62$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.1%40.6%
Portfolio after 10y$204.1K$104.7K
Annual income after 10y$95,539.01$25,725.73
Total dividends collected$172.3K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GARPY vs ABBV ($10,000, DRIP)

YearGARPY PortfolioGARPY Income/yrABBV PortfolioABBV Income/yrGap
1$11,097$397.28$11,559$438.51$462.00ABBV
2$12,501$626.69$13,494$640.86$993.00ABBV
3$14,379$1,003.51$15,951$945.97$1.6KABBV
4$17,027$1,640.85$19,152$1,413.89$2.1KABBV
5$20,980$2,761.89$23,443$2,146.38$2.5KABBV
6$27,287$4,837.66$29,391$3,321.96$2.1KABBV
7← crossover$38,141$8,943.71$37,948$5,265.87+$193.00GARPY
8$58,581$17,770.43$50,795$8,596.74+$7.8KGARPY
9$101,480$38,798.21$71,034$14,549.41+$30.4KGARPY
10$204,122$95,539.01$104,715$25,725.73+$99.4KGARPY

GARPY vs ABBV: Complete Analysis 2026

GARPYStock

Golden Agri-Resources Ltd, an investment holding company, operates as an integrated palm oil plantation company in Europe, China, India, Pakistan, the Middle east, and the United States. It operates in two segments, Plantation and Palm Oil Mills; and Palm, Laurics and Others. The company offers bulk products, such as crude palm oil, palm kernel, palm kernel oil, palm kernel meal, olein, stearin, soybean oil, and soybean meal; oleo chemicals; palm oil based bio-diesel and other renewable resources based energy; and refined products, including cooking oil, margarine, shortening, butter oil substitute, and fats. It also produces processed food products, such as instant noodles, as well as snack products and beverages. The company manages oil palm estates with a total area of 536,013 hectares in Indonesia. In addition, it offers treasury management, building management, business and management consultancy, telecommunication and multimedia, commercial and industrial real estate management, digital analytics; aerial manuring, construction, training, ship management, chartering, and technology product services. Further, the company provides IT consultancy, IT application design, development, and maintenance services; facilities for data center resources and other IT outsourced activities; and port loading, storage, packaging, and transportation service. Additionally, it engages in importing, marketing, and distributing palm oil products; cultivation of ornamental plants; wholesale trade; property investment activities; production and distribution of bottled ionised mineral water and fatty alcohol, acid, derivatives, and other chemical; shipping and logistics; vessels operation; office administration and dormant services; refinery operation; and sale of food and beverage products. The company was incorporated in 1996 and is based in Singapore.

Full GARPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GARPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GARPY vs SCHDGARPY vs JEPIGARPY vs OGARPY vs KOGARPY vs MAINGARPY vs JNJGARPY vs MRKGARPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.